Endometriosis occurs in up to 15% of menstruating women. Abdominal wall involvement is rare and always secondary to an invasive procedure. The authors report the imaging and clinical findings of two patients with subcutaneous endometrioma following cesarean section.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0221-0363(04)97600-7 | DOI Listing |
Int J Mol Sci
December 2024
College of Veterinary Medicine, South China Agricultural University, Guangzhou 540642, China.
Endometriosis is a chronic inflammatory, estrogenic disorder caused by endometrial tissue growth places other than uterine lumen, resulting in infertility and severe pelvic pain. Thymol, an extract of , processes diverse biological properties, including anti-inflammatory, local anesthetic, decongestant, and antiseptic effects. However, the efficacy of thymol in treating endometriosis has still not been explored.
View Article and Find Full Text PDFAdv Sci (Weinh)
December 2024
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China.
Endometriosis affects over 190 million women globally, and effective therapies are urgently needed to address the burden of endometriosis on women's health. Using an artificial intelligence (AI)-driven target discovery platform, two unreported therapeutic targets, guanylate-binding protein 2 (GBP2) and hematopoietic cell kinase (HCK) are identified, along with a drug repurposing target, integrin beta 2 (ITGB2) for the treatment of endometriosis. GBP2, HCK, and ITGB2 are upregulated in human endometriotic specimens.
View Article and Find Full Text PDFRadiol Case Rep
January 2025
Diagnostic radiology department, Collage of Medicine, King Saud University, Riyadh, Saudi Arabia.
The differential diagnosis of abdominal wall lesions is broad and includes Myositis ossificans (MO). MO primarily arises in skeletal muscles, but can also occur around adjacent structures. It typically appears as a soft tissue lesion with peripheral rim of calcification.
View Article and Find Full Text PDFF S Sci
October 2024
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut. Electronic address:
Objective: To use murine avatars for studying human endometriotic lesion response to 2 different hormonal regimens to determine whether progesterone receptor (PR) can prospectively predict response to progestin-based therapy. Endometriosis is a chronic gynecologic disease afflicting 1-in-10 reproductive-age women; however response to medical therapy is highly variable because endometriotic lesions do not consistently respond to first-line progestin-based therapy. We have previously demonstrated in a retrospective study that PR status in lesions is correlated with response to progestins.
View Article and Find Full Text PDFReprod Biomed Online
December 2024
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, People's Republic of China; Key Clinical Specialty of Liaoning Province, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, People's Republic of China. Electronic address:
Research Question: Does LncRNA BANCR promote the malignant transformation of endometriosis by activating the miR-612/CPNE3 pathway?
Design: The expression patterns of BANCR, miR-612 and CPNE3 in normal endometrium, eutopic endometrium from endometriosis, eutopic endometrium or malignant tissues from endometriosis-associated ovarian cancer. On the basis of primary normal endometrial stromal cells (NESC) and eutopic endometrial stromal cells (EESC), the regulatory relationships between BANCR, miR-612 and CPNE3, and the potential mechanisms that promote the malignant transformation of endometriosis, were elucidated in vitro and in vivo.
Results: The expression levels of BANCR and CPNE3 were lowest in normal endometrium, significantly increased in eutopic endometrium (P < 0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!